RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$91.89
+6.31%Nov 3, 2026, 13:20 UTC
Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.1 million, up 79.5% year over year, and a net loss of $42.4 million, or $0.61 per diluted share.
Source:Nov 3, 2026, 12:00 UTC
RHYTHM PHARMACEUTICALS, INC. reported third-quarter 2026 global IMCIVREE net product revenue of $92.1 million, up 29% from the prior quarter.
Source:Nov 3, 2026, 02:59 UTC
RHYTHM PHARMACEUTICALS, INC. and LG Chem Ltd. amended their exclusive license agreement, setting LG Chem Ltd.'s royalty at 1% of global net sales of Rhythm's MC4R agonists and providing for $350 million in additional fixed payments over four years.
Source:Nov 3, 2026, 01:53 UTC
LG Chem Ltd. signed a licensing agreement with RHYTHM PHARMACEUTICALS, INC. valued at $855 million.
Source:Oct 21, 2026, 12:00 UTC
RHYTHM PHARMACEUTICALS, INC. announced that it will host a conference call and webcast on November 3, 2026, to report third-quarter financial results and provide a corporate update.
Source:Sep 28, 2026, 13:10 UTC
Kuehn Law, PLLC is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. breached their fiduciary duties to shareholders.
Source:Sep 10, 2026, 12:00 UTC
Rhythm Pharmaceuticals announced that it and its collaborators will present three posters and three oral presentations on setmelanotide in rare MC4R pathway diseases at the 64th Annual European Society for Paediatric Endocrinology Meeting in Marseille, France, September 8-10, 2026.
Source:Aug 17, 2026, 12:00 UTC
Rhythm Pharmaceuticals appointed Manher (AJ) Joshi as Chief Medical Officer, effective August 17, 2026.
Source:Aug 4, 2026, 12:30 UTC
Rhythm Pharmaceuticals announced preliminary data from an ongoing mid-stage study showing its experimental weekly injectable drug reduced body weight in patients with a rare form of obesity caused by brain damage.
Source:Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE.
Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient start forms received since FDA approval as of June 30, 2026.
Source:Jun 15, 2026, 16:51 UTC
Rhythm Pharmaceuticals reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome.
Source: